Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01411163 · ClinicalTrials.gov registry record · Phase 2
Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01411163: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01411163 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01411163, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to extend the Pre-Crest-X study to further assess the long-term safety and tolerability of up to 30 grams daily creatine in individuals at-risk for Huntington's Disease (HD) and to assess whether biomarkers responsive to creatine in symptomatic individuals are informative in premanifest individuals over a longer duration.
Interventions
- DRUG Creatine monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01411163
The ClinicalTrials.gov registry entry for NCT01411163 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Creatine monohydrate is the first listed.
NCT01411163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01411163 about?
NCT01411163 is a clinical study titled "Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability". The purpose of this clinical trial is to extend the Pre-Crest-X study to further assess the long-term safety and tolerability of up to 30 grams daily creatine in individuals at-risk for Huntington's Disease (HD) and to assess whether biomarkers responsive to creatine in symptomatic individuals are i...
What is the current status of trial NCT01411163?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2010-04. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01411163?
The interventions under investigation include: Creatine monohydrate (DRUG).
Who is sponsoring clinical trial NCT01411163?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.